Serafin Morales Murillo

von Minckwitz, G; Colleoni, M; Kolberg, HC; Morales, S; Santi, P; Tomasevic, Z; Zhang, N; Hanes, V

Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial

LANCET ONCOLOGY 19 987-998. 01/07/2018.

[doi:10.1016/S1470-2045(18)30241-9]

Gianni, L; Mansutti, M; Anton, A; Calvo, L; Bisagni, G; Bermejo, B; Semiglazov, V; Thill, M; Chacon, JI; Chan, A; Morales, S; Alvarez, I; Plazaola, A; Zambetti, M; Redfern, AD; Dittrich, C; Dent, RA; Magazzu, D; De Fato, R; Valagussa, P; Tusquets, I

Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial A Randomized Phase 3 Clinical Trial

JAMA Oncology 4 302-308. 01/03/2018.

[doi:10.1001/jamaoncol.2017.4612]

Gennari A; Sun Z; Hasler-Strub U; Colleoni M; Kennedy MJ; Von Moos R; Cortés J; Vidal MJ; Hennessy B; Walshe J; Parraga KA; Ribi K; Bernhard J; MORALES, S.; Pagani O; Barbeaux A; Borstnar S; Rabaglio-Poretti M; Maibach R; Regan MM; Jerusalem G; International Breast Cancer Study Group, Cancer Trials Ireland and SOLTI Group

A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial

ANNALS OF ONCOLOGY 29 661-668. 01/03/2018.

[doi:10.1093/annonc/mdx772]

Rugo, HS; Tredan, O; Ro, J; Morales, SM; Campone, M; Musolino, A; Afonso, N; Ferreira, M; Park, KH; Cortes, J; Tan, AR; Blum, JL; Eaton, L; Gause, CK; Wang, Z; Im, E; Mauro, DJ; Jones, MB; Denker, A; Baselga, J

A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer

BREAST CANCER RESEARCH AND TREATMENT 165 601-609. 01/10/2017.

[doi:10.1007/s10549-017-4375-5]

Novell, A; Morales, S; Valls J; Panades, MJ; Salud, A; Iglesias, E; Vilardell, F; Matias-Guiu, X; Llombart-Cussac, A

Novel biomarkers in primary breast core biopsies to predict poor response to neoadjuvant chemotherapy and appearance of metastases

HISTOLOGY AND HISTOPATHOLOGY 32 909-915. 01/09/2017.

[doi:10.14670/HH-11-849]

von Minckwitz, G.; Ponomarova, O.; Morales, S.; Zhang, N.; Hanes, V.

Efficacy and safety of biosimilar ABP 980 compared with trastuzumab in HER2 positive early breast cancer

ANNALS OF ONCOLOGY 28 -. 01/09/2017.

Villagrasa Gonzalez, P.; Prat, A.; Oliveira, M.; de la Pena, L.; Gonzalez, X.; Cortes Castan, J.; Rios, J.; Vazquez, J.; Martinez Janez, N.; Perello Martorell, A.; Garau, I.; Martinez de Duenas, E.; Morales, S.; Mele, M.; Bermejo De las Heras, B.; Ciruelos, E.

SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab (with or without letrozole in ER plus ) in previously trastuzumab-pretreated, postmenopausal patients with HER2-positive metastatic breast cancer

ANNALS OF ONCOLOGY 28 -. 01/09/2017.

Morales, S.; Gasol Cudos, A.; Novell Alvarez, A.; Vilardell Villellas, F.; Panades Siurana, M. J.; Canosa Morales, C.; Mele Olive, J.; Iglesias Martinez, E.

Vitamin D as a prognostic factor in triple negative early breast cancer

ANNALS OF ONCOLOGY 28 -. 01/09/2017.

von Minckwitz G; Procter M; de Azambuja E; Zardavas D; Benyunes M; Viale G; Suter T; Arahmani A; Rouchet N; Clark E; Knott A; Lang I; Levy C; Yardley DA; Bines J; Gelber RD; Piccart M; Baselga J; APHINITY Steering Committee and Investigators

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

NEW ENGLAND JOURNAL OF MEDICINE 377 122-131. 13/07/2017.

[doi:10.1056/NEJMoa1703643]

Baselga, J; Morales, SM; Awada, A; Blum, JL; Tan, AR; Ewertz, M; Cortes, J; Moy, B; Ruddy, KJ; Haddad, T; Ciruelos, EM; Vuylsteke, P; Ebbinghaus, S; Im, E; Eaton, L; Pathiraja, K; Gause, C; Mauro, D; Jones, MB; Rugo, HS

A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer

BREAST CANCER RESEARCH AND TREATMENT 163 535-544. 01/06/2017.

[doi:10.1007/s10549-017-4199-3]

Mateo, F; Arenas, EJ; Aguilar, H; Serra-Musach, J; de Garibay, GR; Boni, J; Maicas, M; Du, S; Iorio, F; Herranz-Ors, C; Islam, A; Prado, X; Llorente, A; Petit, A; Vidal, A; Catala, I; Soler, T; Venturas, G; Rojo-Sebastian, A; Serra, H; Cuadras, D; Blanco, I; Lozano, J; Canals, F; Sieuwerts, AM; de Weerd, V; Look, MP; Puertas, S; Garcia, N; Perkins, AS; Bonifaci, N; Skowron, M; Gomez-Baldo, L; Hernandez, V; Martinez-Aranda, A; Martinez-Iniesta, M; Serrat, X; Ceron, J; Brunet, J; Barretina, MP; Gil, M; Falo, C; Fernandez, A; Morilla, I; Pernas, S; Pla, MJ; Andreu, X; Segui, MA; Ballester, R; Castella, E; Nellist, M; Morales, S; Valls, J; Velasco, A; Matias-Guiu, X; Figueras, A; Sanchez-Mut, JV; Sanchez-Cespedes, M; Cordero, A; Gomez-Miragaya, J; Palomero, L; Gomez, A; Gajewski, TF; Cohen, EEW; Jesiotr, M; Bodnar, L; Quintela-Fandino, M; Lopez-Bigas, N; Valdes-Mas, R; Puente, XS; Viñals F; Casanovas, O; Graupera, M; Hernandez-Losa, J; Ramón Y Cajal S; Garcia-Alonso, L; Saez-Rodriguez, J; Esteller, M; Sierra, A; Martin-Martin, N; Matheu, A; Carracedo, A; Gonzalez-Suarez, E; Nanjundan, M; Cortes, J; Lazaro, C; Odero, MD; Martens, JWM; Moreno-Bueno, G; Barcellos-Hoff, MH; Villanueva, A; Gomis, RR; Pujana, MA

Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition

ONCOGENE 36 2737-2749. 11/05/2017.

[doi:10.1038/onc.2016.427]

Llombart-Cussac, A; Cortes, J; Pare, L; Galvan, P; Bermejo, B; Martinez, N; Vidal, M; Pernas, S; Lopez, R; Muñoz M; Nuciforo, P; Morales, S; Oliveira, M; de la Peña L; Pelaez, A; Prat, A

HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial

LANCET ONCOLOGY 18 545-554. 01/04/2017.

[doi:10.1016/S1470-2045(17)30021-9]